Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
10:50am, Wednesday, 26'th Jun 2024
Bagsværd, Denmark, 26 June 2024 – Novo Nordisk today announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK 5.7
Ozempic craze: Novo Nordisk invests $4.1B in US to expand manufacturing
10:11am, Wednesday, 26'th Jun 2024
Novo Nordisk is ramping up the manufacturing capacity of its obesity-related drugs as demand for Wegovy and Ozempic continues to surge. It's pouring $4.1 billion to expand its facility.
The Next 7 Trillion-Dollar Stocks to Buy: June 2024 Edition
07:50am, Wednesday, 26'th Jun 2024
At the time of writing, there are precisely seven trillion dollar stocks overall. One of them, Saudi Aramco, doesn't trade in US markets.
Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy
07:00am, Wednesday, 26'th Jun 2024
Novo Nordisk gains approval in China for blockbuster drug Wegovy. More than 11% of all adults in China live with diabetes - more than any other country in the world. Both Eli Lilly and Novo Nordisk ar
Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion
11:25am, Tuesday, 25'th Jun 2024
Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.
Novo Nordisk Rises as Wegovy Is Approved in China
10:41am, Tuesday, 25'th Jun 2024
American depositary receipts (ADRs) of Danish drugmaker Novo Nordisk (NVO) rose Tuesday on the New York Stock Exchange (NYSE) after the company announced that its popular weight-loss drug Wegovy has
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
10:30am, Tuesday, 25'th Jun 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?
09:45am, Tuesday, 25'th Jun 2024
Novo Nordisk is raking in billions from Ozempic and Wegovy. Pfizer wants in on the action, so it's teaming up with a biotech.
Novo Nordisk gains approval to sell weight-loss drug Wegovy in China
09:38am, Tuesday, 25'th Jun 2024
Novo Nordisk has gained approval to start marketing its blockbuster weight-loss drug Wegovy in China, opening the door for the Danish pharmaceutical giant to further boost sales of the medicine that h
NVO Stock: Novo Nordisk Pops as China Approves Wegovy Weight Loss Drug
09:29am, Tuesday, 25'th Jun 2024
Novo Nordisk (NYSE: NVO ) stock rose on news that China has approved its weight loss drug Wegovy and that the drugmaker will invest $4.1 billion into expanding its U.S. production capacity. The expans
Whole Foods is promoting ‘little luxuries' as the next big food trend
08:48am, Tuesday, 25'th Jun 2024
The supermarket chain, acquired by Amazon AMZN, -1.86% in 2017, sees “little luxuries” — meaning treat-style foods packaged in treat-size portions — as a key emerging trend. Or so said Whole F
Novo Nordisk wins approval for its weight-loss drug from China
08:13am, Tuesday, 25'th Jun 2024
Novo Nordisk A/S (CPH: NOVO-B) climbed 3.0% to an all-time high on Tuesday after China approved the sale of its weight-loss treatment Wegovy. Year-to-date, shares of the pharmaceutical giant are now
Wegovy Approved In China—But Novo Nordisk Promises Existing Patients Priority Amid Shortages
07:56am, Tuesday, 25'th Jun 2024
Ozempic maker Novo Nordisk confirmed Tuesday its popular weight loss drug Wegovy had been approved for sale in China, a key victory for the Danish firm that opens the door to an enormous market, but t
Novo Nordisk's Wegovy weight loss drug approved in China
04:25am, Tuesday, 25'th Jun 2024
Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management. The approval opens up the blockbuster drug for sale for those with obesity a
Ozempic maker Novo Nordisk to spend $4.1bn on North Carolina facility
03:11am, Tuesday, 25'th Jun 2024
Novo Nordisk (NYSE:NVO) is investing $4.1 billion to expand its US manufacturing, focusing on its high-demand weight-loss drugs, Ozempic and Wygovy. The investment will fund a new 1.4 million square
